Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cetylpyridinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.95 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.95 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.95 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 2/20 | 0.95 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.95 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.95 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.95 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.95 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.95 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.95 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.95 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.95 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.95 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.95 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.95 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.95 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.95 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.91 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8770083 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL1331692 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL1331186 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL5085309 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL1547466 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL4540499 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL8650670 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL557155 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Cetylpyridinium SCHEMBL151799 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A | |
| Bromide SCHEMBL5286954 | 0.98 | ACHE (1.00) | RAD52HSP90AA1ACHECHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121573914-A | Preparation method and application of bioactive glass ceramic nano enzyme | 西安交通大学 | 2026-02-27 | — | — | CN | claimed |
| US-20040127461-A1 | Water soluble, randomly substituted partial N-, partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof | ADJUVANT PHARMACEUTICALS, LLC (US) | 2004-07-01 | — | — | US | claimed |
| EP-1425310-A2 | WATER SOLUBLE, RANDOMLY SUBSTITUTED PARTIAL N-, PARTIAL O-ACETYLATED CHITOSAN, PRESERVING COMPOSITIONS CONTAINING CHITOSAN, AND PROCESSES FOR MAKING THEREOF | Technology Resource International Corporation (US) | 2004-06-09 | — | — | EP | claimed |
| US-6716970-B2 | CONTACT LENS PRESERVATIVE SOLUTION | ADJUVANT PHARMACEUTICALS, LLC | 2004-04-06 | — | — | US | claimed |
| US-6495243-B1 | Recording substrates for ink jet printing | XEROX CORPORATION | 2002-12-17 | — | — | US | claimed |
| US-20020177577-A1 | Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof | ADJUVANT PHARMACEUTICALS, LLC | 2002-11-28 | — | — | US | claimed |
| WO-2002085951-A2 | WATER SOLUBLE, RANDOMLY SUBSTITUTED PARTIAL N-, PARTIAL O-ACETYLATED CHITOSAN, PRESERVING COMPOSITIONS CONTAINING CHITOSAN, AND PROCESSES FOR MAKING THEREOF | TECHNOLOGY RESOURCE INTERNATIONAL CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020018732-A1 | Preserving compositions containing chitosan and processes for making water soluble O-acetylated chitosan and chitosan | TECHNOLOGY RESOURCE INTERNATIONAL CORPORATION | 2002-02-14 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5441795-A | Piperazinium compounds | XEROX CORPORATION (US) | 1995-08-15 | — | — | US | claimed |
| EP-0615858-A1 | Transparent recording sheets | XEROX CORPORATION (US) | 1994-09-21 | — | — | EP | claimed |
| EP-0615855-A1 | Recording sheets containing pyridinium and/or piperazinum compounds | XEROX CORPORATION (US) | 1994-09-21 | — | — | EP | claimed |
| US-5330823-A | Transparent recording sheets | XEROX CORPORATION (US) | 1994-07-19 | — | — | US | claimed |
| EP-0346655-B1 | AN IMPROVED METHOD FOR PREPARING POLYMER SURFACES FOR SUBSEQUENT PLATING THEREON, AND IMPROVED METAL-PLATED PLASTIC ARTICLES MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 1993-08-18 | — | — | EP | claimed |
| US-4917452-A | Liquid crystal optical switching device | UCE, INC. (US) | 1990-04-17 | — | — | US | claimed |
| EP-0346655-A1 | An improved method for preparing polymer surfaces for subsequent plating thereon, and improved metal-plated plastic articles made therefrom | GENERAL ELECTRIC COMPANY (US) | 1989-12-20 | — | — | EP | claimed |
| US-4873136-A | MILD ETCHING; REMOVAL OF RESIDUAL FILM WITH CATIONIC SURFACTANT | GENERAL ELECTRIC COMPANY (US) | 1989-10-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177577-A1 | Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof | PIGS, CSGALNACT1, OGA | ACHE 886/4885CHRM2 802/4885ADRA2A 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.